Morning Markets March E-Mini S&P 500 futures (ESH24 ) are down -0.30%, and March Nasdaq 100 E-Mini futures (NQH24 ) are down -0.19%. Stock index futures this morning are mildly lower as higher bond yields...
March S&P 500 E-Mini futures (ESH24) are down -0.24%, and March Nasdaq 100 E-Mini futures (NQH24) are down -0.12% this morning as U.S. Treasury yields climbed on relatively hawkish comments from Federal...
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: David...
Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.16%. U.S. stock index futures this morning recovered from overnight...
June S&P 500 futures (ESM23) are up +0.05%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.15% this morning after three major U.S. benchmark indices finished the regular session mixed as an unexpected...
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 79.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 60% and 27.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...
4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further...
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...